Meta-analysis of the efficacy and safety of rituximab in the treatment of primary Sjögren’s syndrome

Research has demonstrated that rituximab can decrease the levels of serum IgG and serum B cells in individuals with Sjögren's syndrome. Additionally, it can significantly enhance the ESSPRI score and pain VAS score in patients. However, it does not have a notable impact on glandular function. The occurrence of adverse effects was like that of the control group. Given the scarcity of research, the findings may be influenced by bias, and a substantial quantity of rigorous investigations is required to validate them.